Tocilizumab, Anti-IL-6 Receptor Monoclonal Antibody : Randomized, Double-blind, Placebo-controlled, Withdrawal Phase III Trial of Efficacy and Safety against Systemic-onset Juvenile Idiopathic Arthritis
Tocilizumab, Anti-IL-6 Receptor Monoclonal Antibody : Randomized, Double-blind, Placebo-controlled, Withdrawal Phase III Trial of Efficacy and Safety against Systemic-onset Juvenile Idiopathic Arthritis
复制标题
托珠单抗，抗 IL-6 受体单克隆抗体：针对全身性幼年特发性关节炎的有效性和安全性的随机、双盲、安慰剂对照、停药 III 期试验
DOI：
--
复制
发表时间：
--
期刊：
影响因子：
--
通讯作者：
Imagawa T.
中科院分区：
文献类型：
--
作者：
Yokota S;Imagawa T.
